"The discussion highlights the potential of $DR, drawing comparisons to Biovica's more affordable testing solutions, suggesting that there may be an undervaluation or lack of awareness among investors. Concerns about the stock's visibility and market interest are also noted, indicating a need for broader engagement in the investment community."